Results were announced in a study of fibro patients who had previously taken the drug Milnacipran for an average of three years. In a double-blind study, half the study group of 300 people were continued on Milnacipran while the other half were given a placebo. The half that were given a placebo showed a greater loss of therapeutic effects than those that were kept on Milnacipran.
Milnacipran is a serotonin–norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorders. Of the group of patients who were kept on the drug 81% maintained a clinically meaningful pain response.
Read more: Milnacipran Study
Powered by Facebook Comments